Invention Grant
- Patent Title: Anti-human urothelial carcinoma of supercritical carbon dioxide extract of Cinnamomum subavenium, and the preparation process and uses
- Patent Title (中): 樟脑超临界二氧化碳提取物抗人尿路上皮癌及其制备方法和用途
-
Application No.: US13426136Application Date: 2012-03-21
-
Publication No.: US08669377B2Publication Date: 2014-03-11
- Inventor: Jih-Heng Li , A-Mei Huang , Chung-Yi Chen , Pei-Jung Lien , Chiung-Hui Liu
- Applicant: Jih-Heng Li , A-Mei Huang , Chung-Yi Chen , Pei-Jung Lien , Chiung-Hui Liu
- Applicant Address: TW
- Assignee: Kaohsiung Medical University
- Current Assignee: Kaohsiung Medical University
- Current Assignee Address: TW
- Agency: Volpe and Koenig, P.C.
- Priority: TW100141688A 20111115
- Main IPC: C07D307/02
- IPC: C07D307/02

Abstract:
What is disclosed in the invention is a preparation method of a supercritical Cinnamomum subavenium extract, which is made from the material, the dried stem of C. subavenium. The extract is obtained by extracting C. subavenium which is pulverized as particles with supercritical carbon dioxide fluid. The C. subavenium extract or its active ingredient, subamolide A, can be used to inhibit the growth of human urothelial carcinoma cell lines. In addition, the C. subavenium extract (or subamolide A) is able to synergistically inhibit the growth of human urothelial carcinoma cell lines with cisplatin (CDDP) or gemcitabine (Gem). Therefore, the C. subavenium extract (or subamolide A) can be an anticancer drug alone, or forms a pharmaceutical composition with CDDP (or Gem) to treat with cancers in respect of urinary system.
Public/Granted literature
Information query